

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	10/715,417	Confirmation No.:	5850
Applicant	:	Eivind Per Thor STRATEN <i>et al.</i>		
Filed	:	November 19, 2003		
Title	:	SURVIVIN-DERIVED PEPTIDES AND USE THEREOF		
TC/Art Unit	:	1644		
Examiner:	:	Marianne DiBrino, Ph.D.		
Docket No.	:	60820.000004		
Customer No.	:	21967		

MAIL STOP AMENDMENT

Commissioner of Patents
P.O. Box 1450
Alexandria, VA 22313-1450

LETTER REGARDING SUBSTANCE OF INTERVIEW

Sir,

In accordance with 37 C.F.R. § 1.133(b) and M.P.E.P. § 713.04, Applicants herein provide a summary of the personal interview of June 26, 2008 between Robin Teskin, Robert Lampe, III, and Examiner Marianne DiBrino, Ph.D. Applicants appreciate the courtesies extended by the Examiner during this interview. During the interview, the rejections of record were discussed. The rejections under 35 U.S.C. § 112, 1st and 2nd paragraph concerning the cell lines recited in claim 24 were discussed, and Applicant may introduce additional information concerning the cell lines, such as commercial availability. The Examiner suggested (for the claims drawn only to the peptide) adding functional language in order to potentially overcome the written description rejection of record. The prior art rejections based on the Anderson references were discussed, and no agreement was reached.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: July 28, 2008

HUNTON & WILLIAMS LLP
Intellectual Property Department
1900 K Street, N.W., Suite 1200
Washington, DC 20006-1109
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)

By:


Robin L. Teskin
Reg. No. 35,030

Robert C. Lampe III
Registration No. 51,914